Merck & Co.
AWARDS
NEWS
Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.
Vaccinex, a company developing a novel approach to treat both cancer and neurodegenerative disease through the inhibition of SEMA4D, will pair its lead asset with Merck’s vaunted checkpoint inhibitor Keytruda.
Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.
It was a busy week for clinical trial updates. Here’s a look.
Merck, known as MSD outside of the U.S. and Canada, announced on Wednesday that it has seen positive results regarding the safety, tolerability and immunogenicity of V114 in two Phase III studies.
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
JOBS
IN THE PRESS